US approves SP acquisition of Organon BioSciences
The US Federal Trade Commission has approved Schering-Plough's acquisition of Organon BioSciences, the parent company of Intervet. To allay competitive concerns, Schering-Plough will be required to divest three of its poultry vaccines in the US. In October, the company agreed to divest twenty products as a condition of approval from the European Commission (Animal Pharm No 624, p 1). Schering-Plough said the divestitures will not have a significant impact on the company's financial results.